Home › PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia
 

Keywords :   


PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia

2015-11-03 03:42:29| drugdiscoveryonline Home Page

PixarBio Corporation recently announced that it has filed an application with the US FDA Office of Orphan Products Development, for orphan drug status of our NeuroRelease TN (NR-TN) drug candidate for the treatment of Trigeminal Neuralgia (TN)

Tags: corporation drug submission announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05PCMC addresses latest printing trends at \'Power Packs Live\'
13.05More than 50 sessions scheduled for drupa cube
13.05IDENTCO highlights automation and PCB labeling at PCB East
13.05INDA, AFS Partner on FiltXPO 2025 Conference Program
13.05Bell adds 14,174 net retail IPTV subscribers in 1Q 2024
13.05Reynders chooses Vetaphone for surface treatment
13.05Polyvel Makes Organizational Changes
13.05Sun Chemical receives FTA Excellence in Flexography Award
More »